Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The association of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) is thought to be rare, and its optimal treatment is unknown. Of 130 consecutive patients with a diagnosis of PBC, we identified 12 cases (9.2%) of overlap syndrome (10 females, 2 males; median age, 50 years) strictly defined by the presence of at least two of the three recognized biochemical, serological, and histological criteria of each disease. One patient had initially pure PBC and developed AIH characterized by a flare of alanine transaminase (ALT) (1,330 IU/L; N < 35), elevated immunoglobulin G (IgG) (42 g/L; N < 14.0), and presence of anti-smooth muscle antibodies (ASMA) after 20 months of ursodeoxycholic acid (UDCA) therapy. A complete clinical and biochemical remission was achieved under combination of corticosteroids and UDCA. Eleven patients had features of both diseases at presentation: high serum levels of alkaline phosphatase (AP) (median: 280 IU/L; N < 100), ALT (140 IU/L), and IgG (30.8 g/L), presence of mitochondrial antibodies (n = 9) or ASMA (n = 9), florid bile duct lesions (n = 8), and moderate or severe periportal or periseptal lymphocytic piecemeal necrosis (n = 11). UDCA (13-15 mg/kg/d) given alone in 5 patients induced a significant decrease in biochemical cholestasis but not in ALT levels, and liver fibrosis progressed in 3 patients. Corticosteroids given alone in 6 patients induced a significant decrease in ALT, IgG, and AP levels, but none had a biochemical normalization. The patients with persistently abnormal liver tests under either UDCA or corticosteroids received both UDCA and corticosteroids. A further marked biochemical improvement was observed, and all patients became asymptomatic. We conclude that, in patients with PBC: 1) overlap syndrome with AIH is not rare; 2) flares of AIH may occur either spontaneously or under UDCA; and 3) combination of UDCA and corticosteroids is required in most patients to obtain a complete biochemical response. Overlap syndrome may represent an important and unrecognized cause of resistance to UDCA in patients with PBC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The available data suggest that patients who fulfil the Paris criteria for the diagnosis of AIH either at presentation or during the course of their PBC may benefit from additional immunosuppression in the short-and medium-term [160,162,175,176].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [162]
In the citing paper
“A simplified AIH scoring system has more recently been developed, and, when applied to PBC patients, it identified fewer patients meeting probable AIH criteria than the older scoring system did (4% versus 12%).(125)(126)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [126]
In the citing paper
“Criteria have been proposed by the Paris group for ‘true’ PBC/AIH overlap,272 with two out of three of (a) ALT >5 x ULN, (b) IgG >2 x ULN or positive anti-SMA and (c) liver biopsy with ‘moderate or severe periportal or periseptal lymphocytic piecemeal necrosis (interface hepatitis)’ being suggested as diagnostic of overlap in the context of a PBC diagnosis.”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [272]
Citations
Cites
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
Bedossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,003
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Self-citationUrsodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Kaplan, M. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611213352107 · Cited by 455
Calmus, Y., Gane, P., Rouger, P., & Poupon, R. (1990) · Hepatology · doi:10.1002/hep.1840110104 · Cited by 303
Self-citationInvernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M. (1997) · Hepatology · doi:10.1002/hep.510250507 · Cited by 293
Michieletti, P., Wanless, I. R., Katz, A., Scheuer, P. J., Yeaman, S. J., Bassendine, M. F., Palmer, J. M., & Heathcote, E. J. (1994) · Gut · doi:10.1136/gut.35.2.260 · Cited by 236
Autoimmune cholangiopathy: Part of the spectrum of autoimmune chronic active hepatitis
Ben-Ari, Z., Dhillon, A. P., & Sherlock, S. (1993) · Hepatology · doi:10.1002/hep.1840180103 · Cited by 218
Krawitt, E. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604043341406 · Cited by 206
A controlled trial of prednisolone treatment in primary biliary cirrhosis
Mitchison, H. C., Palmer, J. M., Bassendine, M. F., Watson, A. J., Record, C. O., & James, O. F. W. (1992) · Journal of Hepatology · doi:10.1016/0168-8278(92)90065-w · Cited by 199
Goodman, Z. D., McNally, P. R., Davis, D. R., & Ishak, K. G. (1995) · Digestive Diseases and Sciences · doi:10.1007/bf02065530 · Cited by 178
Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis
Czaja, A. J., Carpenter, H. A., & Manns, M. P. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90160-e · Cited by 155
Calmus, Y., Guechot, J., Podevin, P., Bonnefis, M. T., GIBOUDEAU, J., & Poupon, R. Y. (1992) · Hepatology · doi:10.1002/hep.1840160317 · Cited by 153
Self-citationA UNIFIED CONCEPT OF AUTOIMMUNE HEPATITIS
Doniach, D., & Walker, J. G. (1969) · The Lancet · doi:10.1016/s0140-6736(69)92072-8 · Cited by 150
Kl�ppel, G., Seifert, G., Lindner, H., Dammermann, R., Sack, H. J., & Berg, P. A. (1977) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00432159 · Cited by 113
Kim, W. R., Poterucha, J. J., Jorgensen, R. A., Batts, K. P., Homburger, H. A., Dickson, E. R., Krom, R. A. F., Wiesner, R. H., & Lindor, K. D. (1997) · Hepatology · doi:10.1002/hep.510260103 · Cited by 107
Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis
Kenny, R. P., Czaja, A. J., Ludwig, J., & Dickson, E. R. (1986) · Digestive Diseases and Sciences · doi:10.1007/bf01296447 · Cited by 106
Colombato, L. A., Alvarez, F., Côté, J., & Huet, P.-M. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90829-x · Cited by 104
Geubel, A., Baggenstoss, A. H., & Summerskill, W. H. J. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80453-2 · Cited by 100
Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse
Calmus, Y., Weill, B. J., Ozier, Y. M., Chéreau, C., Houssin, D. P., & Poupon, R. Y. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90855-s · Cited by 97 · cited 1×
“Corticosteroids 208 (91-350) 52 (31-147) ,.”
Self-citationDavis, P. A., Leung, P. S. C., Manns, M. P., Kaplan, M., Muñoz, S. J., Gorin, F. A., Dickson, R. E., Krawitt, E. L., Coppel, R. L., & Gershwin, E. M. (1992) · Hepatology · doi:10.1002/hep.1840160505 · Cited by 68
Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome
Duclos‐Vallée, J., Hadengue, A., Ganne‐Carrié, N., Robin, E. T., Degott, C., & Erlinger, S. (1995) · Digestive Diseases and Sciences · doi:10.1007/bf02064201 · Cited by 65
Kinetics of anti-M2 antibodies after liver transplantation for primary biliary cirrhosis
Dubel, L., Farges, O., Bismuth, H., Sebagh, M., Homberg, J., & Johanet, C. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80033-6 · Cited by 61
Impaired Nonspecific Cellular Immunity in Experimental Cholestasis
Roughneen, P. T., Drath, D. B., Kulkarni, A. D., & Rowlands, B. J. (1987) · Annals of Surgery · doi:10.1097/00000658-198711000-00004 · Cited by 47 · cited 1×
“Corticosteroids 208 (91-350) 52 (31-147) ,.”
Chronic active hepatitis with histological features of primary biliary cirrhosis
Okuno, T., Seto, Y., Okanoue, T., & Takino, T. (1987) · Digestive Diseases and Sciences · doi:10.1007/bf01296147 · Cited by 43
The hepatitis‐associated bile duct lesion
Vyberg, M. (1993) · Liver International · doi:10.1111/j.1600-0676.1993.tb00648.x · Cited by 43
Primary Biliary Cirrhosis -- A First Step in Prolonging Survival
Kaplan, M. M. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301912 · Cited by 34
A 33-Year-Old Woman with an Autoimmune Syndrome
Carrougher, J. G., Shaffer, R. T., Canales, L., & Goodman, Z. D. (1991) · Seminars in Liver Disease · doi:10.1055/s-2008-1040444 · Cited by 30
Hepatitis and Cholestasis in A Middle–Aged Woman
Perrillo, R. P., Mason, A. L., Jacob, S., & Gerber, M. A. (1996) · Hepatology · doi:10.1002/hep.510240342 · Cited by 22
Chronic active hepatitis with cholestatic features. I. A clinical and immunological study.
Shouval, D., Levij, I. S., & ELIAKIM, M. (1979) · PubMed · Cited by 14
Heathcote, J. E., Cauch-Dudek, K., Walker, V., Bailey, R. J., Blendis, L. M., Ghent, C. N., Michieletti, P., Minuk, G. Y., Pappas, C. S., Scully, L. J., et al. (1994) · Hepatology · doi:10.1002/hep.1840190512 · Cited by 2
Research works printed but not linked: 2
- Shouval, 1979, Chronic active hepatitis with cholestatic features, Am J Gastroenterol, 72, 542
- Nakamura, 1995, Effect of ursodeoxycholic acid (UDCA) on patients with type 1 auto-immune hepatitis [Abstract], Gastroenterology, 107, 958A
Cited by
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
“Because of the limited applicability of the different diagnostic scores, another approach based on the major characteristics of PBC and AIH has been proposed and requires the presence of at least 2 of the 3 accepted criteria of both diseases for diagnosing PBC–AIH overlap syndrome (Table 4) [57] whereby histologic evi…”
BackgroundMethodHirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
“Given the high specificity of serological markers, liver biopsy is not necessary for the diagnosis of PBC; however, it is still essential when PBC-specific antibodies are absent, or when co-existent AIH or non-alcoholic steatohepatitis (NASH) is suspected.”
InfluentialDiagnosis and management of autoimmune hepatitis
Manns, M. P., Czaja, A. J., Gorham, J. D., Krawitt, E. L., Mieli-Vergani, G., Vergani, D., & Vierling, J. M. (2010) · Hepatology · doi:10.1002/hep.23584 · Cited by 1,442
EASL Clinical Practice Guidelines: autoimmune hepatitis
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.030 · Cited by 1,245
“The ‘‘Paris criteria’’ are currently the most commonly used tool for diagnosing AIH-PBC variant form as attested by the presence of at least two of the three accepted key criteria of each disease namely, for PBC: 1) alkaline phosphatase (ALP) P2 upper normal limit (ULN) or c-glutamyl-transpeptidase (c-GT) P5 ULN; 2) p…”
BackgroundMethod(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Metadata
- Authors
- Chazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R.
- Affiliations
- Assistance Publique – Hôpitaux de Paris (FR)
- Corresponding author
- Chazouillères, Olivier
- Venue
- Hepatology
- Published
- 1998-08
- Volume
- 28
- Issue
- 2
- Pages
- 296-301
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2056147648
- Semantic Scholar
- e5878dda2aeaf614ad753e5c66ea3a752edfb605
- Cited by
- 746
- References
- 34
- Citations by year
- 2026: 21 · 2025: 29 · 2024: 37 · 2023: 37 · 2022: 32 · 2021: 31 · 2020: 31 · 2019: 27 · 2018: 38 · 2017: 31 · 2016: 28 · 2015: 36 · 2014: 32 · 2013: 32 · 2012: 33
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6240 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary biliary cirrhosis, autoimmune hepatitis, overlap syndrome, ursodeoxycholic acid, corticosteroids, combination therapy, treatment resistance, anti-smooth muscle antibodies, antimitochondrial antibodies, cholestasis, liver fibrosis, IgG, anti-amyloid antibodies, remission, disease flares, bile duct lesions
- MeSH terms
- Adrenal Cortex Hormones, Adult, Aged, Cholagogues and Choleretics, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Liver Cirrhosis, Biliary, Male, Middle Aged, Syndrome, Ursodeoxycholic Acid, Treatment Outcome, Hepatitis, Autoimmune
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.